0KF3 Stock Overview
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Palatin Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.88 |
| 52 Week High | US$5.45 |
| 52 Week Low | US$1.46 |
| Beta | 0.89 |
| 1 Month Change | 16.28% |
| 3 Month Change | -34.17% |
| 1 Year Change | -28.89% |
| 3 Year Change | -86.75% |
| 5 Year Change | -92.41% |
| Change since IPO | -91.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0KF3 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -3.7% | -2.4% | -1.4% |
| 1Y | -28.9% | -29.6% | -2.4% |
Return vs Industry: 0KF3 matched the UK Biotechs industry which returned -28.5% over the past year.
Return vs Market: 0KF3 underperformed the UK Market which returned -1% over the past year.
Price Volatility
| 0KF3 volatility | |
|---|---|
| 0KF3 Average Weekly Movement | 24.5% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0KF3's share price has been volatile over the past 3 months.
Volatility Over Time: 0KF3's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 34 | Carl Spana | palatin.com |
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases.
Palatin Technologies, Inc. Fundamentals Summary
| 0KF3 fundamental statistics | |
|---|---|
| Market cap | US$30.18m |
| Earnings (TTM) | -US$35.04m |
| Revenue (TTM) | US$7.10m |
4.3x
P/S Ratio-0.9x
P/E RatioIs 0KF3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0KF3 income statement (TTM) | |
|---|---|
| Revenue | US$7.10m |
| Cost of Revenue | US$23.14m |
| Gross Profit | -US$16.04m |
| Other Expenses | US$19.01m |
| Earnings | -US$35.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.17 |
| Gross Margin | -225.96% |
| Net Profit Margin | -493.74% |
| Debt/Equity Ratio | 0% |
How did 0KF3 perform over the long term?
See historical performance and comparison